GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paratek Pharmaceuticals Inc (NAS:PRTK) » Definitions » Cyclically Adjusted PB Ratio

Paratek Pharmaceuticals (Paratek Pharmaceuticals) Cyclically Adjusted PB Ratio : 0.30 (As of May. 05, 2024)


View and export this data going back to 2006. Start your Free Trial

What is Paratek Pharmaceuticals Cyclically Adjusted PB Ratio?

As of today (2024-05-05), Paratek Pharmaceuticals's current share price is $2.23. Paratek Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 was $7.34. Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.30.

The historical rank and industry rank for Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:

PRTK' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.11   Med: 0.28   Max: 0.65
Current: 0.36

During the past years, Paratek Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 0.65. The lowest was 0.11. And the median was 0.28.

PRTK's Cyclically Adjusted PB Ratio is not ranked
in the Biotechnology industry.
Industry Median: 1.75 vs PRTK: 0.36

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Paratek Pharmaceuticals's adjusted book value per share data for the three months ended in Jun. 2023 was $-3.515. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $7.34 for the trailing ten years ended in Jun. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Chart

Paratek Pharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.17 0.28 0.28 0.19

Paratek Pharmaceuticals Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.16 0.25 0.19 0.33 0.31

Competitive Comparison of Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.



Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=2.23/7.34
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Paratek Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2023 is calculated as:

For example, Paratek Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Jun. 2023 was:

Adj_Book=Book Value per Share/CPI of Jun. 2023 (Change)*Current CPI (Jun. 2023)
=-3.515/128.7287*128.7287
=-3.515

Current CPI (Jun. 2023) = 128.7287.

Paratek Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201309 48.695 98.790 63.452
201312 45.690 98.326 59.818
201403 44.333 99.695 57.244
201406 26.221 100.560 33.566
201409 21.427 100.428 27.465
201412 6.605 99.070 8.582
201503 5.863 99.621 7.576
201506 8.028 100.684 10.264
201509 6.828 100.392 8.755
201512 5.749 99.792 7.416
201603 4.142 100.470 5.307
201606 4.705 101.688 5.956
201609 3.777 101.861 4.773
201612 3.065 101.863 3.873
201703 3.295 102.862 4.124
201706 4.108 103.349 5.117
201709 3.581 104.136 4.427
201712 2.952 104.011 3.654
201803 3.523 105.290 4.307
201806 2.696 106.317 3.264
201809 1.813 106.507 2.191
201812 1.475 105.998 1.791
201903 0.495 107.251 0.594
201906 -0.421 108.070 -0.501
201909 -1.234 108.329 -1.466
201912 -0.995 108.420 -1.181
202003 -1.304 108.902 -1.541
202006 -1.401 108.767 -1.658
202009 -1.750 109.815 -2.051
202012 -2.198 109.897 -2.575
202103 -2.537 111.754 -2.922
202106 -2.069 114.631 -2.323
202109 -2.099 115.734 -2.335
202112 -2.471 117.630 -2.704
202203 -2.646 121.301 -2.808
202206 -2.727 125.017 -2.808
202209 -2.997 125.227 -3.081
202212 -3.019 125.222 -3.104
202303 -3.300 127.348 -3.336
202306 -3.515 128.729 -3.515

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Paratek Pharmaceuticals  (NAS:PRTK) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Paratek Pharmaceuticals Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Paratek Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Paratek Pharmaceuticals (Paratek Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
75 Park Plaza, 4th Floor, Boston, MA, USA, 02116
Paratek Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's medical research is based on tetracycline chemistry and biology to create two antibacterials: omadacycline and sarecycline. NUZYRA (Omadacycline) is an antibacterial for skin infections and treatment of community-acquired bacterial pneumonia. SEYSARA (Sarecycline) is designed for use in the treatment of acne and rosacea. Paratek Pharmaceuticals is also involved in research to treat multiple sclerosis, spinal muscular atrophy, and systemic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel diseases.
Executives
Minnie Baylor-henry director C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Kristine Peterson director AMARIN CORPORATION, MYSTIC PACKER BLDG., 12 ROOSEVELT AVENUE, MYSTIC CT 06355
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Jeffrey Stein director 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Thomas John Dietz director C/O TRANSCEPT PHARMACEUTICAL, INC., 1003 W. CUTTING BLVD, STE 110, PT. RICHMOND CA 94804
Evan Loh director, officer: CEO 75 KNEELAND STREET, BOSTON MA 02111
William M. Haskel officer: CLO, General Counsel & Sec. ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Adam Woodrow officer: President & Chief Commercial C/O PARATEK PHARMACEUTICALS, INC., 75 KNEELAND STREET, BOSTON MA 02111
Randall B. Brenner officer: Chief Development & Regulatory C/O PARATEK PHARMACEUTICALS, INC., 75 PARK PLAZA, 4TH FLOOR, BOSTON MA 02116
Robert S Radie director 101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Rolf K Hoffmann director LORBEERWEG 7, WEGGIS V8 CH-6353
Michael Bigham director, officer: Exec. Chairman of the Board 890 WINTER STREET, WALTHAM MA 02451
James D Dondero 10 percent owner 300 CRESCENT COURT, SUITE 700, DALLAS TX 75201
Douglas W. Pagan officer: Chief Financial Officer 75 KNEELAND STREET, BOSTON MA 02111
Omega Fund Iv, L.p. 10 percent owner 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199